EHA 2017 | Can chemoimmunotherapy in CLL treatment be replaced with novel agents?
Barbara Eichhorst, MD, from University Hospital Cologne, Cologne, Germany, provides us an insight into the outcomes of a Phase II trial evaluating the efficacy and safety of a combined regimen of obinutuzumab and venetoclax in patients with chronic lymphocytic leukemia (CLL) (NCT02242942). She also outlines the background and outcomes of a Phase III trial evaluating if standard chemoimmunotherapy (FCR, BR) in frontline treatment of CLL patients can be replaced by combinations of targeted drugs (venetoclax, ibrutinib) with anti-CD20-antibodies (rituximab, obinutuzumab) (NCT02950051) and notes that the future of CLL treatment is likely to be chemoimmunotherapy-free. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
